Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial

被引：0

作者：

Razeq, Hikmat Abdel ^{[1
]}

Cottu, Paul ^{[2
]}

Ring, Alistair ^{[3
]}

De laurentiis, Michelino ^{[4
]}

Lu, Janice ^{[5
]}

Azim, Hamdy ^{[6
]}

Zamagni, Claudio ^{[7
]}

Zhou, Katie ^{[8
]}

Wu, Jiwen ^{[8
]}

Menon-Singh, Lakshmi ^{[8
]}

Martin, Miguel ^{[9
]}

机构：

[1] King Hussein Canc Ctr, Amman, Jordan

[2] Curie Inst, Paris, France

[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[4] Natl Canc Inst Pascale Fdn, Naples, Italy

[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Cairo Univ, Cairo, Egypt

[7] Bologna Univ Hosp, St Orsola Malpighi Polyclin, Bologna, Italy

[8] Novartis Pharmaceut, E Hanover, NJ USA

[9] Gregorio Maranon Gen Univ Hosp, Madrid, Spain

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS10-10

引用

页数：1

共 50 条

[1] Ribociclib plus letrozole in male patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
Campone, Mario
De Laurentiis, Michelino
Zamagni, Claudio
Kudryavcev, Igor
Agterof, Mariette
Brown-Glaberman, Ursa
Palacova, Marketa
Chatterjee, Sanjoy
Menon-Singh, Lakshmi
Wu, Jiwen
Zhou, Katie
Martin, Miguel
[J]. CANCER RESEARCH, 2021, 81 (04)
[2] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
Lu, Janice
Cottu, Paul
Martin, Miguel
Zamagni, Claudio
Prat, Aleix
Chia, Stephen
Jerusalem, Guy
Rajappa, Senthil
Timcheva, Constanta
Zhukova, Lyudmila
Zhou, Katie
Wu, Jiwen
Menon-Singh, Lakshmi
De Laurentiis, Michelino
[J]. CANCER RESEARCH, 2021, 81 (04)
[3] Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
Mario Campone
Michelino De Laurentiis
Claudio Zamagni
Igor Kudryavcev
Mariëtte Agterof
Ursa Brown-Glaberman
Markéta Palácová
Sanjoy Chatterjee
Lakshmi Menon-Singh
Jiwen Wu
Miguel Martín
[J]. Breast Cancer Research and Treatment, 2022, 193 : 95 - 103
[4] Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
Campone, Mario
De Laurentiis, Michelino
Zamagni, Claudio
Kudryavcev, Igor
Agterof, Mariette
Brown-Glaberman, Ursa
Palacova, Marketa
Chatterjee, Sanjoy
Menon-Singh, Lakshmi
Wu, Jiwen
Martin, Miguel
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (01) : 95 - 103
[5] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and central nervous system metastases: Subgroup analysis of the phase IIIb CompLEEment-1 trial
Cottu, Paul
De Laurentiis, Michelino
Marchetti, Paolo
Coltelli, Luigi
Califaretti, Nadia
Debled, Marc
Patil, Shekar
Evron, Ella
Duhoux, Francois
Menon-Singh, Lakshmi
Wu, Jiwen
Zhou, Katie
Bofill, Javier Salvador
[J]. CANCER RESEARCH, 2021, 81 (04)
[6] Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Cottu, P. H.
Ring, A.
Marchetti, P.
Cardoso, F.
Salvador, J.
Neven, P.
Papazisis, K.
Campone, M.
Bachelot, T.
Menon-Singh, L.
Wu, J.
Zhou, K.
De laurentiis, M.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S379 - S380
[7] Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
Cottu, Paul
Ring, Alistair
Abdel-Razeq, Hikmat
Marchetti, Paolo
Cardoso, Fatima
Bofill, Javier Salvador
Martin, Miguel
Menon-Singh, Lakshmi
Wu, Jiwen
De Laurentiis, Michelino
[J]. BREAST, 2022, 62 : 75 - 83
[8] Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) from the CompLEEment-1 trial
Campone, M.
De laurentiis, M.
Zamagni, C.
Kudryavcev, I.
Agterof, M.
Brown-Glaberman, U.
Palacova, M.
Chatterjee, S.
Menon-Singh, L.
Wu, J.
Zhou, K.
Martin, M.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[9] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Abdel-Razeq, H.
Cottu, P. H.
Ring, A.
De laurentiis, M.
Lu, J.
Azim, H. A.
Zamagni, C.
Zhou, K.
Wu, J.
Menon, L.
Martin, M.
[J]. ANNALS OF ONCOLOGY, 2018, 29
[10] Ribociclib (RIB) plus letrozole (LET) in Asian patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2L-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
Chatterjee, S.
Yusof, M. Md
Dejthevaporn, T.
Chung, W-P.
Galvez, C. G.
Sunpaweravong, P.
Cheng, A.
Abesamis-Tiambeng, M. L. T.
Michelle, S. O. Y.
Menon-Singh, L.
Wu, J.
Zhou, K.
Azim, H.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1260 - S1261

← 1 2 3 4 5 →